

AMENDMENTS TO THE CLAIMS

Please amend the claims as follows:

Claims 1-5 (Canceled).

Claim 6 (Original). A compound selected from the group consisting of
4-(4-Fluoro-*1H*-pyrrolo[2,3-b]pyridin-5-yloxy)-5-methyl-pyrrolo[2,1-f][1,2,4]triazin-6-ol,
(*R*)-1-[4-(4-Fluoro-*1H*-pyrrolo[2,3-b]pyridin-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]-propan-2-ol,
(*S*)-1-[4-(4-Fluoro-*1H*-pyrrolo[2,3-b]pyridin-5-yloxy)-5-methyl-pyrrolo[2,1-f][1,2,4]triazin-6-yloxy]-propan-2-ol,
(*R*)-1-[4-(4-Fluoro-2-methyl-*1H*-pyrrolo[2,3-b]pyridin-5-yloxy)-5-methyl-pyrrolo[2,1-f][1,2,4]triazin-6-yloxy]-propan-2-ol,
(*R*)-2-[4-(4-Fluoro-*1H*-pyrrolo[2,3-b]pyridin-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]-1-methylethylamine,
(*R*)-2-[4-(4-Fluoro-2-methyl-*1H*-pyrrolo[2,3-b]pyridin-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]-1-methyl-ethylamine,
2-[4-(4-Fluoro-*1H*-pyrrolo[2,3-b]pyridin-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]-ethylamine,
(4-Fluoro-*1H*-pyrrolo[2,3-b]pyridin-5-yl)-[5-isopropyl-6-(3-methyl-[1,2,4]oxadiazol-5-yl)-pyrrolo[2,1-f][1,2,4]triazin-4-yl]-amine,
(4-Fluoro-*1H*-pyrrolo[2,3-b]pyridin-5-yl)-[5-isopropyl-6-(5-methyl-[1,3,4]oxadiazol-2-yl)-pyrrolo[2,1-f][1,2,4]triazin-4-yl]-amine,
(4-Fluoro-2-methyl-*1H*-pyrrolo[2,3-b]pyridin-5-yl)-[5-isopropyl-6-(5-methyl-[1,3,4]oxadiazol-2-yl)-pyrrolo[2,1-f][1,2,4]triazin-4-yl]-amine, and
[5-Isopropyl-6-(5-methyl-[1,3,4]oxadiazol-2-yl)-pyrrolo[2,1-f][1,2,4]triazin-4-yl]-(2-methyl-*1H*-pyrrolo[2,3-b]pyridin-5-yl)-amine.

Claim 7 (Canceled).

Claim 8 (Previously presented). A pharmaceutical composition comprising one or more of the compounds of Claim 6 and a pharmaceutically acceptable carrier therefor.

Claim 9 (Canceled).

Claim 10 (Previously presented). A pharmaceutical composition comprising one or more compounds of Claim 6 in combination with a pharmaceutically acceptable carrier and one or more additional anti-cancer or cytotoxic agent.

Claim 11 (Currently amended). The pharmaceutical composition of Claim 9 10 , wherein said anti-cancer or cytotoxic agent is selected from the group consisting of: linomide, inhibitors of integrin $\alpha v\beta 3$ function, angiostatin, razoxane, tamoxifen, toremifene, raloxifene, droloxitene, iodoxifene, megestrol acetate, anastrozole, letrozole, borazole, exemestane, flutamide, nilutamide, bicalutamide, cyproterone acetate, gosereline acetate, leuprolide, finasteride, herceptin, metalloproteinase inhibitors, inhibitors of urokinase plasminogen activator receptor function, growth factor antibodies, growth factor receptor antibodies, bevacizumab, cetuximab, tyrosine kinase inhibitors, serine/threonine kinase inhibitors, methotrexate, 5-fluorouracil, purine, adenosine analogues, cytosine arabinoside, doxorubicin, daunomycin, epirubicin, idarubicin, mitomycin-C, dactinomycin, mithramycin, cisplatin, carboplatin, nitrogen mustard, melphalan, chlorambucil, busulphan, cyclophosphamide, ifosfamide, nitrosoureas, thiotapec, vincristine, paclitaxel, docetaxel, epothilone analogs, discodermolide analogs, eleutherobin analogs, etoposide, teniposide, amsacrine, topotecan, irinotecan, flavopyridols, bortezomib and biological response modifiers.

Claims 12-20 (Canceled).